NNNN - Company ID 0001982708
The table below shows Anbio Biotechnology's income statement line items across its last 4 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $8.65M | $8.19M | $6.71M | $23.54M |
| Cost of revenue | $1.10M | $2.30M | $3.35M | $10.98M |
| Gross profit | $7.54M | $5.89M | $3.36M | $12.56M |
| R&D | $201.31K | $454.23K | $134.70K | $200.00K |
| SG&A | $1.57M | $3.44M | $1.27M | $2.17M |
| Operating income | $5.77M | $2.00M | $1.96M | $10.20M |
Anbio Biotechnology reported annual revenue of $8.65M for fiscal year 2025. That is up 5.6% from $8.19M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Income tax | $0.00 | $0.00 | $0.00 | - |
| Net income | $6.40M | $2.37M | $2.25M | $10.01M |
| EPS (diluted) | $0.15 | $0.06 | $0.10 | $100.11K |